Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma.
Rodríguez Otero P, Towle K, Cope S, Caisip C, Davies FE, Delforge M, Weisel K, Marshall TS, Karampampa K, Ayers D, Mojebi A, Braverman J, Farrell J, Dhanda D. Rodríguez Otero P, et al. Among authors: karampampa k. Leuk Lymphoma. 2023 Nov-Dec;64(11):1864-1869. doi: 10.1080/10428194.2023.2235042. Epub 2023 Jul 27. Leuk Lymphoma. 2023. PMID: 37497883 No abstract available.
Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab.
Karampampa K, Gyllensten H, Friberg E, Murley C, Kavaliunas A, Hillert J, Olsson T, Alexanderson K. Karampampa K, et al. BMJ Open. 2023 May 16;13(5):e067516. doi: 10.1136/bmjopen-2022-067516. BMJ Open. 2023. PMID: 37192793 Free PMC article.
Excess costs of multiple sclerosis: a register-based study in Sweden.
Murley C, Tinghög P, Teni FS, Machado A, Alexanderson K, Hillert J, Karampampa K, Friberg E. Murley C, et al. Among authors: karampampa k. Eur J Health Econ. 2023 Nov;24(8):1357-1371. doi: 10.1007/s10198-022-01547-6. Epub 2022 Nov 23. Eur J Health Econ. 2023. PMID: 36418785 Free PMC article.
Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden.
Karampampa K, Gyllensten H, Murley C, Alexanderson K, Kavaliunas A, Olsson T, Manouchehrinia A, Hillert J, Friberg E. Karampampa K, et al. Mult Scler J Exp Transl Clin. 2022 Apr 24;8(2):20552173221092411. doi: 10.1177/20552173221092411. eCollection 2022 Apr-Jun. Mult Scler J Exp Transl Clin. 2022. PMID: 35496759 Free PMC article.
Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group.
Murley C, Tinghög P, Alexanderson K, Hillert J, Friberg E, Karampampa K. Murley C, et al. Among authors: karampampa k. Pharmacoeconomics. 2021 Jul;39(7):835-851. doi: 10.1007/s40273-021-01035-4. Epub 2021 May 10. Pharmacoeconomics. 2021. PMID: 33970446 Free PMC article.
28 results